Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest OncoGenex Pharmaceuticals Inc. Stories

2012-01-04 07:00:00

BOTHELL, Wash. and VANCOUVER, British Columbia, Jan. 4, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data evaluating its investigational compound custirsen (OGX-011/TV-1011) in patients with advanced non-small cell lung cancer (NSCLC) were published in an early online version of the January 2012 issue of the Journal of Thoracic Oncology. These data provide additional clinical evidence for the potential of custirsen, a drug designed to...

2011-10-26 15:20:00

BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 26, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that pre-clinical data evaluating its investigational compound, OGX-427, in pancreatic cancer was published online in Cell Death and Disease. OGX-427 is designed to reduce levels of heat shock protein 27, or Hsp27, a protein that is highly expressed in many types of cancer. Overexpression of Hsp27 is believed to be an important factor leading to...

2011-10-20 15:20:00

BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 20, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has initiated patient enrollment in a randomized, Phase II clinical trial evaluating OGX-427, an inhibitor of heat shock protein 27 (Hsp27), in patients with advanced bladder cancer. The trial is designed to assess the potential survival benefit of combining OGX-427 with standard first-line chemotherapy, as well as its safety, tolerability and...

2011-10-18 15:00:00

BOTHELL, WA and VANCOUVER, Oct. 18, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Company's third quarter 2011 financial results will be released on Thursday, November 3, 2011 after the NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide an update on the business. To access the webcast,...

2011-09-15 15:00:00

BOTHELL, WA and VANCOUVER, Sept. 15, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Michelle Burris, OncoGenex' Executive Vice President of Operations and Chief Financial Officer, will provide a corporate presentation at the UBS Global Life Sciences conference on Tuesday, September 20 at 9:30 a.m. at the Grand Hyatt Hotel in New York City. The live audio webcast can be accessed through the Investor Relations page of the OncoGenex website...

2011-09-06 11:24:00

BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 6, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen (OGX-011/TV-1011), were published in the September issues of the journals Clinical Cancer Research and Cancer Research. Custirsen inhibits the production of clusterin, a protein commonly over-produced in cancer cells and...

2011-09-01 15:00:00

BOTHELL, WA and VANCOUVER, BC, Sept. 1, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that senior management will present at the following investor conferences: -- Scott Cormack, OncoGenex' President and Chief Executive Officer, will provide a corporate presentation at the Stifel Nicolaus HealthcareConference on Wednesday, September 7 at 8:00 a.m. ET at the Four Seasons Hotel in Boston. --...

2011-08-10 07:00:00

BOTHELL, WA and VANCOUVER, BC, Aug. 10, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Michelle Burris, OncoGenex' Executive Vice President of Operations and Chief Financial Officer, will be presenting at the 2011 Wedbush Securities Life Sciences Management Access Conference. The OncoGenex corporate presentation will take place on Wednesday, August 17(th) at 3:35pm ET at Le Parker Meridien Hotel in New York City. The...

2011-08-04 16:05:00

BOTHELL, Wash. and VANCOUVER, Aug. 4, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an update on current events and activities and announced its second quarter financial results. Second Quarter 2011 Highlights Expected timing of results from the survival primary endpoint for the custirsen SYNERGY Phase 3 clinical trial remains unchanged at Q4 2013. During discussions regarding the SATURN Special Protocol Assessment, or SPA, amendment, FDA stated that...

2011-07-28 07:00:00

BOTHELL, WA and VANCOUVER, July 28, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Company's second quarter 2011 financial results will be released on Thursday, August 4, 2011 after the NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide an update on the...